Please login to the form below

Not currently logged in
Email:
Password:

Santhera CEO Klaus Schollmeier joins SuppreMol

He has experience at ING BHF-Bank, BASF, Knoll and Abbott

Santhera CEO Klaus Schollmeier joins SuppreMolFormer CEO of Santhera Pharmaceuticals Klaus Schollmeier has joined Germany-based biopharma SuppreMol as CEO.

Dr Schollmeier (pictured right) had served as CEO of Santhera since its formation in 2004, and was appointed chairman in October 2011.

He has both senior scientific and business experience, previously serving as managing director healthcare-biotechnology at ING BHF-Bank; head of oncology-immunology research at BASF; and general manager for BASF's operations in Western Europe.

Prior to his time at BASF, he held senior roles at Knoll and Abbott.

In his new position at autoimmune disease specialists SuppreMol, Schollmeier succeeds Professor Peter Buckell who retires.

Dr Thomas Hecht, chairman of the company's advisory board, paid tribute to Prof Buckell for his “long-standing commitment” as he welcomed Dr Schollmeier.

He said: "The company has a very promising product candidate for the treatment of autoimmune diseases in phase II clinical development with important clinical and regulatory milestones ahead. Dr Schollmeier will bring the necessary experience to the company to advance SuppreMol's products towards a Biologics License Application.”

This product is SM101, which is being investigated for its use in the treatment of primary immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE).

5th April 2013

From: Research, Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
TRIDUCIVE

Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics